Medicine and Dentistry
Androgen Receptor
73%
Bladder Cancer
47%
Androgen
31%
Enzalutamide
31%
Androgen Receptor Antagonist
26%
Cancer Cell
15%
Cell Migration
15%
Assay
15%
Cell Invasion
15%
Cancer Growth
15%
Androstanolone
15%
Cells
10%
Therapeutic Procedure
10%
Cell Proliferation
10%
Short Hairpin RNA
10%
Growth
10%
Tumor Progression
10%
Xenograft
10%
Antiandrogen
10%
Bicalutamide
10%
Real Time Polymerase Chain Reaction
5%
Combination Therapy
5%
Programmed Cell Death
5%
Flow Cytometry
5%
Observation
5%
Interleukin 6
5%
Cell Viability
5%
Feeding
5%
Reporter Gene
5%
Wound Healing
5%
Gelatinase A
5%
Flutamide
5%
Hydroxyflutamide
5%
Cell Viability Assay
5%
Biochemistry, Genetics and Molecular Biology
Androgen Receptor
100%
Enzalutamide
31%
Growth
26%
Receptor Antagonist
26%
Cancer Cell
21%
Cell Migration
15%
Cell Invasion
15%
Mouse
10%
RNA
10%
Cell Proliferation
10%
Agonist
10%
Cell Viability
10%
Bicalutamide
10%
Real-Time Polymerase Chain Reaction
5%
Interleukin 6
5%
Apoptosis
5%
Matrix Metalloproteinase
5%
Cell Growth
5%
Reporter Gene
5%
Flow Cytometry
5%
Wound Healing Assay
5%
Pharmacology, Toxicology and Pharmaceutical Science
Androgen Receptor
73%
Bladder Cancer
47%
Enzalutamide
31%
Androgen
31%
Androgen Receptor Antagonist
26%
Agonist
21%
Cancer Growth
15%
Androstanolone
15%
Mouse
10%
Tumor Growth
10%
Antiandrogen
10%
Short Hairpin RNA
10%
Bicalutamide
10%
Interleukin 6
5%
Gelatinase A
5%
Flutamide
5%
Wound Healing
5%
Hydroxyflutamide
5%